Use of antidepressant drugs in transplant recipients.

Jiwon Kim, Paula Phongsamran, Susie Park

Journal: Progress in transplantation (Aliso Viejo, Calif.) 2004;14(2):98-104

PMID: 15264454

Abstract

Depression is the most prevalent psychiatric disorder in transplant recipients and may lead to noncompliance and negative outcomes without psychosocial and pharmacologic interventions. The pharmacologic treatment of depression in this patient population is complicated by complex immunosuppressant drug regimens and multiple potential drug interactions that can adversely affect the newly transplanted organs. This review provides a brief overview of the currently available antidepressant medications and highlights the clinically important features each class of agents in transplant recipients. Newer agents selective serotonin reuptake inhibitors, venlafaxine, bupropion, nefazodone, and mirtazapine are discussed as well as tricyclic antidepressants and monoamine oxidase inhibitors. A brief discussion of St. John's wort and its impact on posttransplant drug therapy is also included.

Address: University of Southern California, School of Pharmacy, Los Angeles, California, USA.

DOI: 10.1177/152692480401400204

Link outs

Free resources

Medical:

https://medlineplus.gov/organtransplantation.html

Subscription / membership required

Full Text Sources:

https://journals.sagepub.com/doi/10.1177/152692480...

MeSH Terms: Adrenergic alpha-2 Receptor Antagonists, Adrenergic alpha-Antagonists, Antidepressive Agents, Antidepressive Agents, Tricyclic, Depressive Disorder, Drug Monitoring, Humans, Hypericum, Monoamine Oxidase Inhibitors, Neurotransmitter Uptake Inhibitors, Organ Transplantation, Patient Selection, Phytotherapy, Safety, Serotonin 5-HT2 Receptor Antagonists, Treatment Outcome, Treatment Refusal